|
**Overview**: **SARS-CoV-2 Biomarkers Basic Profile****Introduction**: The SARS-CoV-2 Biomarkers Basic Profile is a diagnostic tool designed to monitor COVID-19 biomarkers using serum samples. Associated with conditions like severe COVID-19 and related complications, these disorders present with fever, shortness of breath, and severe complications if untreated, particularly in individuals with confirmed or suspected COVID-19. Per the 2023 Biochemistry and Immunology guidelines, the test employs biochemistry and immunology with spectrophotometry and immunoassay technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for COVID-19 monitoring in clinical settings. This diagnostic falls under COVID-19 monitoring and targets individuals with suspected or confirmed COVID-19, addressing the challenge of accurate biomarker assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: SARS-CoV-2 Bio Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry and immunology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2020s by infectious disease labs, this test advanced COVID-19 biomarker monitoring.**Purpose**: The test screens for 30 parameters including CRP to guide COVID-19 assessment, assess inflammatory and metabolic markers, and inform treatment and prevention strategies.**Test Parameters**: 1. CRP, 2. D-Dimer, 3. Ferritin, 4. IL-6, 5. Procalcitonin, 6. LDH, 7. Total Bilirubin, 8. AST, 9. ALT, 10. ALP, 11. Total Protein, 12. Albumin, 13. Globulin, 14. Creatinine, 15. Urea, 16. Sodium, 17. Potassium, 18. Chloride, 19. Calcium, 20. Phosphorus, 21. Troponin I, 22. NT-proBNP, 23. Glucose, 24. HbA1c, 25. Total Cholesterol, 26. HDL, 27. LDL, 28. Triglycerides, 29. CPK, 30. Magnesium.**Pretest Condition**: Fasting 10-12 hours required; patients should report fever, shortness of breath, or recent COVID-19 symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on fever, shortness of breath, prior COVID-19 reactions, or family history of respiratory infections, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated COVID-19 including respiratory failure, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry and immunoassay and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent immunosuppressive therapy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible COVID-19 complications, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in infectious disease should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Chest CT or PCR for confirmation.**Test Limitations**: The test may produce false negatives in early infection stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Biochemistry and Immunology Guidelines 2023, Journal of Infectious Diseases 2024, Chemistry 2025. |
